Do NOACs (apixaban, dabigatran, rivaroxaban) reduce the risk of ischemic stroke, ICH, or major bleeding compared to warfarin in patients with nonvalvular atrial fibrillation and previous stroke or transient ischemic attack?
Patients with nonvalvular atrial fibrillation and previous stroke or transient ischemic attack
Apixaban, dabigatran, and rivaroxaban (NOACs)
Warfarin
Ischemic stroke, intracranial hemorrhage (ICH), or major bleeding riskhard clinical
Apixaban, dabigatran, and rivaroxaban demonstrate consistent effectiveness and safety compared to warfarin in patients with nonvalvular atrial fibrillation and a prior history of stroke or TIA.
Results from our study of the 3 NOACs versus warfarin in nonvalvular atrial fibrillation patients with a previous history of stroke/transient ischemic attack are relatively consistent with their respective phase III trials and previous stroke/transient ischemic attack subgroup analyses. All NOACs seemed no worse than warfarin in respect to ischemic stroke, ICH, or major bleeding risk.
Building similarity graph...
Analyzing shared references across papers
Loading...
Craig I Coleman
W. Frank Peacock
Thomas J. Bunz
Stroke
University of Connecticut
Hartford Financial Services (United States)
Hartford Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Coleman et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69dbb5b2387cf70698688882 — DOI: https://doi.org/10.1161/strokeaha.117.017474